Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Defence Therapeutics Inc (DTC.CN)

Defence Therapeutics Inc (DTC.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 36,429
  • Shares Outstanding, K 45,537
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,344 K
  • 60-Month Beta 1.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade DTC.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings $-0.03 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

    TSX Bottom 100 Stocks

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6800 +11.76%
on 06/27/24
1.1800 -35.59%
on 06/06/24
-0.3400 (-30.91%)
since 06/03/24
3-Month
0.6800 +11.76%
on 06/27/24
1.7400 -56.32%
on 05/02/24
-0.8900 (-53.94%)
since 04/03/24
52-Week
0.6800 +11.76%
on 06/27/24
3.1000 -75.48%
on 07/06/23
-2.1600 (-73.97%)
since 06/30/23

Most Recent Stories

More News
Defence's AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)
Defence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)
Defence's Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)
Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024

Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)
Defence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)
Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)
Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine

Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth

Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)
Defence Therapeutics Announces Warrant Terms Amendment

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies...

DTCFF : 0.6177 (-4.97%)
DTC.CN : 0.7600 (-5.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research...

See More

Key Turning Points

3rd Resistance Point 0.9333
2nd Resistance Point 0.9067
1st Resistance Point 0.8533
Last Price 0.7600
1st Support Level 0.7733
2nd Support Level 0.7467
3rd Support Level 0.6933

See More

52-Week High 3.1000
Fibonacci 61.8% 2.1756
Fibonacci 50% 1.8900
Fibonacci 38.2% 1.6044
Last Price 0.7600
52-Week Low 0.6800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar